Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?

@article{Rodrigues2005ImpactOC,
  title={Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?},
  author={A. David Rodrigues},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2005},
  volume={33 11},
  pages={1567-75}
}
The market withdrawals of rofecoxib (Vioxx) and valdecoxib (Bextra) have focused considerable attention on the side effect profiles of cyclooxygenase (COX) inhibitors. As a result, attempts will be made to identify risk factors in the hope that physicians might be able to ensure patient safety. At first glance, CYP2C9 genotype might be considered a risk factor because many COX inhibitors are CYP2C9 substrates in vitro. This observation has led some to hypothesize that a reduction in clearance… CONTINUE READING